Myriad Genetics (MYGN) Reports Revenue Growth, Strategic Shifts

 

• Myriad Genetics (MYGN, Financial) reported solid Q2 2025 revenue of $213 million, fueled by strong growth in MyRisk HCT oncology tests.
• Wall Street analysts predict an average price target of $7.19, suggesting significant upside potential.
• GuruFocus estimates indicate a substantial potential upside based on the GF Value metric.

Strong Quarter Boosted by Oncology Test Demand

Myriad Genetics (MYGN) achieved impressive revenue of $213 million in Q2 2025, marking a robust performance largely driven by a 14% rise in the volume of MyRisk HCT oncology tests. The GeneSight test also contributed with a 5% increase in demand. Despite a 7% dip in prenatal test volumes, Myriad Genetics remains strategically committed to enhancing growth and profitability within the Cancer Care Continuum.

Wall Street Analysts' Perspective

Analyst projections present an intriguing outlook for Myriad Genetics Inc (MYGN, Financial), with 13 analysts providing a one-year average price target of $7.19. Price targets range from a high estimate of $18.00 to a low of $3.50, illustrating a considerable variance in expectations. The average target suggests a potential upside of 85.85% from the current stock price of $3.87.

https://www.gurufocus.com/news/3039061/myriad-genetics-mygn-reports-revenue-growth-strategic-shifts